Stany Michael P, Bidus Michael A, Reed Elizabeth J, Kaplan Keith J, McHale Michael T, Rose G Scott, Elkas John C
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Building 2, Walter Reed Army Medical Center, 6900 Georgia Ave., NW, Washington, DC 20307, USA.
Gynecol Oncol. 2006 Apr;101(1):82-5. doi: 10.1016/j.ygyno.2005.09.050. Epub 2005 Nov 10.
To determine the prevalence of HR-HPV DNA in ASC-US Pap smears following implementation of the Bethesda 2001 classification system.
A computer database of Pap smears obtained within Department of the Army medical facilities was queried for the study period August 2002 to June 2004. All ASC-US Pap smears that underwent reflex testing for HR-HPV DNA were included. Additional clinical and demographic data were obtained from facilities within the US northeast region to evaluate the differences in ASC-US and SIL rates between the current and former Bethesda classification systems.
550,000 Pap smears were collected during the study period. The HR-HPV prevalence was 40.8% (95% confidence interval [CI] = 40.3 to 41.3) among 40,870 patients with ASC-US Pap smears. Within the northeast region, the HR-HPV prevalence in ASC-US Pap smears decreased from 61.2% (95% CI = 57.4 to 64.8%) in patients 18-22 years old to 24.9% (95% CI = 23.1 to 26.8%) in patients age 29 and older. When comparing the two classification systems, significant increases in both ASC-H and SIL and decreases in ASC-US were appreciated after the institution of Bethesda system 2001.
In our large, diverse cohort, the implementation of the Bethesda II system has resulted in a decrease in ASC-US Pap smear results. Additionally, the prevalence of HR-HPV in the ASC-US population was 40.8%, significantly lower than the rate noted in the ALTS trial under the Bethesda I classification system.
确定在采用2001年贝塞斯达分类系统后,非典型鳞状细胞意义不明确(ASC-US)巴氏涂片检查中高危型人乳头瘤病毒(HR-HPV)DNA的流行率。
查询2002年8月至2004年6月期间美国陆军医疗设施部门获得的巴氏涂片计算机数据库。纳入所有接受HR-HPV DNA反射检测的ASC-US巴氏涂片。从美国东北地区的医疗机构获取额外的临床和人口统计学数据,以评估当前和以前的贝塞斯达分类系统之间ASC-US和鳞状上皮内病变(SIL)率的差异。
研究期间共收集了550,000份巴氏涂片。在40,870例ASC-US巴氏涂片患者中,HR-HPV流行率为40.8%(95%置信区间[CI]=40.3至41.3)。在东北地区,ASC-US巴氏涂片中HR-HPV流行率从18-22岁患者中的61.2%(95%CI=57.4至64.8%)降至29岁及以上患者中的24.9%(95%CI=23.1至26.8%)。比较两种分类系统时,2001年贝塞斯达系统实施后,非典型鳞状细胞不排除高度病变(ASC-H)和SIL均显著增加,而ASC-US显著减少。
在我们这个规模大且多样化的队列中,贝塞斯达II系统的实施导致ASC-US巴氏涂片结果减少。此外,ASC-US人群中HR-HPV的流行率为40.8%,显著低于贝塞斯达I分类系统下的美国ASC-US/LSIL Triage Study(ALTS)试验中记录的值。